Market calls for fewer drug reps
Specialty drugs bring about the need for a sales force with more clinical knowledge
Today's big pharmaceutical sales forces will be replaced by a smaller, smarter and more effective sales model, according to a new report by PricewaterhouseCoopers (PwC), "Pharma 2020: Marketing the Future."
The report says the new trend will also require pharmaceutical companies to recruit and train people who can negotiate with increasingly powerful healthcare payers and pharmacoeconomic assessment agencies. Big Pharma's announcement at the end of 2008 to cut more than 60,000 jobs globally-many in sales and marketing-was seen as one response to market shifts.
The PwC report says that between 1996 and 2005, the number of U.S. sales representatives had increased nearly 50% to 100,000, while the number of practicing physicians only rose by 26%. Now the sales forces are shrinking back.
"The role of the drug company salesforce is migrating from product promotion to healthcare promotion," says Todd Evans, a director in PwC's Pharmaceutical & Life Sciences practice. "This change will require a recasting and retraining of what the sales force is and who it targets. We are moving beyond the narrow role of promoting a product to focusing on value, which we need to recognize instead of price. There are implications to the way we represent pharmaceutical products to payers; they want to see outcomes and the results of comparative effectiveness."
In its report, PwC outlines a variety of changes:
David Calabrese of OptumRx Talks New Role, Market Insulin Prices and Other Topics 'On His Mind'
April 13th 2023In this month’s episode of the "What's On Your Mind podcast," Peter Wehrwein, managing editor of MHE connects with the now Chief Clinical Officer of OptumRx Integrated Pharmacies, David Calabrese. In this conversation, David touches on his transition in January as OptumRx’s former chief pharmacy officer and market president of health plans and PBMs to his new role as Chief Clinical Officer where he now focuses more on things such as specialty pharmacy to home delivery — with an overall goal of creating whole-patient care. Throughout the conversation, Calabrese also touched on the market’s hot topic of insulin prices and behavioral health services within the OptumRx community, among other topics.
Listen
Upended: Can PBM Transparency Succeed?
March 6th 2024Simmering tensions in the pharmacy benefit management (PBM) industry have turned into fault lines. The PBMs challenging the "big three" have formed a trade association. Purchaser coalitions want change. The head of the industry's trade group says inherent marketplace friction has spilled over into political friction.
Read More
Briana Contreras, editor of Managed Healthcare Executive, spoke with Nancy Lurker, CEO and president of EyePoint Pharmaceuticals. Nancy shared a bit about EyePoint and how the organization’s innovative therapies are addressing patient needs through eye care, and most importantly, she addressed C-Suite positions like the CEO role. Nancy shared advice for those seeking to reach the CEO level, especially toward women in healthcare and other roles, and what it takes to run a biopharma company.
Listen
The deliberate disconnection of Change Healthcare to ring fence a cyberattack entered its seventh day today. Prescribers are finding ways to get pharmacy claims processed, and UnitedHealth Group says disruption to the dispensing of prescriptions has been minimal. But independent pharmacies want more information and protection from financial consequences from pharmacy benefit managers.
Read More
